Clinical Trial Update: Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating an anti-CD3 and anti-CD7 ricin A immunotoxin for acute graft-versus-host disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Anti-CD3 & Anti-CD7 Ricin A Immunotoxin (CD3/CD7-targeted ricin A immunotoxin)

Snippet

Sponsor: Henogen | Conditions: Acute Graft Versus Host Disease | Phase 1, Phase 2 | Status: WITHDRAWN